Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

he Company from Janssen under the collaboration and license agreement.Pharmacyclics, Inc.
Condensed Consolidated Statements of Operations(unaudited; in thousands, except per share data) Three Months EndedSix Months EndedDec. 31,Sep. 30,Dec. 31,Dec. 31, Dec. 31,20122012201120122011Revenue:  License and milestone revenue

$ 55,000$ 100,000$ 77,605$ 155,000$   77,605  Collaboration services revenue

2,9632,6952985,658335Total revenue

57,963102,69577,903160,65877,940Operating expenses*:  Research and Development

27,56719,07212,07646,63923,324  Less: Excess amounts related to Research and Development

(17,306)--(17,306)-Research and Development, net

10,26119,07212,07629,33323,324  General and Administrative

7,2254,8683,94412,0937,294  Less: Excess amounts related to General and Administrative

(819)--(819)-General and Administrative, net

6,4064,8683,94411,2747,294Total operating expenses

16,66723,94016,02040,60730,618Income from operations

41,29678,75561,883120,05147,322Interest and other income, net

77522112944Income before income taxes

41,37378,80761,904120,18047,366Income tax benefit (provision)

554(3,201)(5,651)(2,647)(5,651)Net income

$ 41,927$   75,606$ 56,253$ 117,533$   41,715Net income per share:Basic

$
.60$
.09$
.82$
.69$
.61Diluted

$
.56$
.02$
.78$
.58$
.58Weighted average shares used to computenet income per share:Basic

69,83969,51268,65869,67668,491Diluted

74,39974,45671,72574,40871,312* Includes share-based compensation as follows:Research and development

$   2,767$
2,590$   1,701$
5,357$
3,239General and administrative

1,5035766752,0791,301$   4,270$
3,166$   2,376$
7,436$
4,540Reconciliation of Selected GAAP Measures to Non-GAAP Measures (1) '/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 Carahsoft and ... Thursday, January 23, 2014 at 2pm EST (11am PST), ... The topic focuses on how technology can turn raw, ... decisions for government agencies. The online webinar will last ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
(Date:1/14/2014)... USA, and Cardiff, UK (PRWEB) January 13, 2014 ... technology development leader with more than 20 years in ... for optics and photonics . Hainsey will serve as ... delighted to have Dr. Hainsey join SPIE as our ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... Study Also Show Minimal Effect on Heart Rhythm ... Changes in Schizophrenia Patients, VIENNA, Austria, ... being developed by Organon -- is effective,in treating acute manic episodes ... studies, were presented this week at,the 20th European College of Neuropsychopharmacology ...
... Bristol-Myers Squibb,Company (NYSE: BMY ) announced today ... granted approval of IXEMPRA(TM) (ixabepilone) as,monotherapy for the ... cancer in patients whose tumors are resistant or ... also granted,approval of IXEMPRA in combination with capecitabine ...
... Senior Management Team, ROCKVILLE, Md., Oct. 16 ... pharmaceutical company developing,therapeutics for the treatment of cancer ... Ph.D. has been appointed its Senior Vice,President, Research ... an,executive officer of EntreMed by the Board of ...
Cached Biology Technology:Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 2Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 3Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 4Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 5Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 6FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 2FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 3FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 4FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 5FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 6FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 7EntreMed Appoints Senior Vice President of Research and Development 2EntreMed Appoints Senior Vice President of Research and Development 3EntreMed Appoints Senior Vice President of Research and Development 4
(Date:4/17/2014)... German . ... demanded of him, he can expect his premises to be ... of the consequences is enough to make restaurant owners pay ... lay their eggs in other birds, nests. If the host ... their revenge by destroying the entire nest. Consequently, it is ...
(Date:4/17/2014)... stark warning on the possible effects of gases such ... times that of carbon dioxide. Now a team of ... fully regenerable electron acceptors which helps explain why large ... being released to the atmosphere. However, there are worries ... into a vicious cycle to release large amounts of ...
(Date:4/17/2014)... wild animals and plant life, but there,s an invisible ... in the soil, decomposing organic matter and releasing carbon ... fungi play in ecological systems, their identities have only ... generated a genetic map of more than 10,000 species ... this week in the Proceedings of the National ...
Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3Methane climate change risk suggested by proof of redox cycling of humic substances 2Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3
... was until now believed that nocturnally migrating songbirds, while ... long, challenging trans-continental migrations, could at least release anti-predator ... study by Spanish and Swiss scientists ?published this week ... not without predation risk for passerines. , A ...
... be reunited with its owner than a lost cat, according to two ... that 71 percent of lost dogs were found, compared to just 53 ... recovered dogs were found by a call or visit to an animal ... wore a dog license or identification tag at the time of its ...
... mean big things for cancer patients in the future. Gary ... of Kentucky published their findings today in Nature Genetics, an ... stem cell gene and its protein product, Laxetin, and building ... to the identification of the gene itself. This is the ...
Cached Biology News:Bats prey on nocturnally migrating songbirds 2Bats prey on nocturnally migrating songbirds 3Bats prey on nocturnally migrating songbirds 4Lost dogs found more often than lost cats, study suggests 2Lost dogs found more often than lost cats, study suggests 3Researchers first to map gene that regulates adult stem cell growth 2
This depletion cocktail is tailored to deplete IgE-bearing (I.e. basophils and mast cells) from whole blood...
... gels The SpinPrep Gel DNA Kit enables efficient ... 12,000 bp in size from agarose gels. The procedure ... by adsorption of the DNA to a silica membrane ... the purified DNA is eluted in low-salt buffer. Each ...
This kit is designed to select cells labeled with fluorescein isothiocyanate- (FITC-) conjugated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
... This microscope is described by end-users to ... incorporates the fundamentals of light microscopy and ... small footprint, it does not require much ... a busy lab environment. The DM-BA300 combines ...
Biology Products: